Trial Profile
Expanded Access Study of MEK162 in Metastatic or Unresectable NRAS Mutation-positive Melanoma
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 31 Jul 2014
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 31 Jul 2014 New trial record